Neil Kumar’s BridgeBio team locks in a $2.4B partnership as their next drug gets a snap review at the FDA

Michael Henderson

BridgeBio $BBIO is on a roll.

At the end of February, they won an approval for their first drug, a therapy used to treat extremely rare cases of molybdenum cofactor deficiency type A. In...

Click to view original post